1. Market Research
  2. > Life Science Intermediates Market Consolidation: Who will not survive?

Life Science Intermediates Market Consolidation: Who will not survive?

  • January 2014
  • -
  • Venture Planning Group
  • -
  • 35 pages

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive? This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies.

The report presents:

-Internally developed and acquired technologies, and related capabilities.
-Proprietary technologies and patent litigations.

The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.
Contains 35 pages

Table Of Contents

Life Science Intermediates Market Consolidation: Who will not survive?
1. BASF
2. Cambrex
3. Clariant
4. DowPharma
5. DSM
6. Evonik
7. Lanxess
8. Lonza
9. Novasep
10. Rhodia

For each company, the report presents:

- Internally developed and acquired technologies, and related capabilities.

- Proprietary technologies and patent litigations.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.